Arthur E. Frankel - Publications

Wake Forest University, Winston-Salem, NC, United States 
 2013- University of Texas Southwestern Medical Center, Dallas, TX, United States 
Oncology, Biochemistry, Molecular Biology

120 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Brenner A, Falchook G, Patel M, Infante J, Arkenau H, Dean E, Borazanci E, Lopez J, Moore K, Schmid P, Frankel A, Jones S, McCulloch W, Kemble G, Grimmer K, et al. Abstract P6-11-09: Heavily pre-treated breast cancer patients show promising responses in the first in human study of the first-In-class fatty acid synthase (FASN) inhibitor, TVB-2640 in combination with paclitaxel Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P6-11-09  0.32
2015 Bekdash A, Darwish M, Timsah Z, Kassab E, Ghanem H, Najjar V, Ghosn M, Nasser S, El-Hajj H, Bazerbachi A, Liu S, Leppla SH, Frankel AE, Abi-Habib RJ. Phospho-MEK1/2 and uPAR Expression Determine Sensitivity of AML Blasts to a Urokinase-Activated Anthrax Lethal Toxin (PrAgU2/LF). Translational Oncology. 8: 347-57. PMID 26500025 DOI: 10.1016/J.Tranon.2015.07.001  0.752
2015 Khoury O, Ghazale N, Stone E, El-Sibai M, Frankel AE, Abi-Habib RJ. Human recombinant arginase I (Co)-PEG5000 [HuArgI (Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human glioblastoma cells. Journal of Neuro-Oncology. 122: 75-85. PMID 25567351 DOI: 10.1016/S0959-8049(14)50671-5  0.737
2015 Angelot-Delettre F, Roggy A, Frankel AE, Lamarthee B, Seilles E, Biichle S, Royer B, Deconinck E, Rowinsky EK, Brooks C, Bardet V, Benet B, Bennani H, Benseddik Z, Debliquis A, et al. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent. Haematologica. 100: 223-30. PMID 25381130 DOI: 10.3324/haematol.2014.111740  0.381
2014 Frolova O, Benito J, Brooks C, Wang RY, Korchin B, Rowinsky EK, Cortes J, Kantarjian H, Andreeff M, Frankel AE, Konopleva M. SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia. British Journal of Haematology. 166: 862-74. PMID 24942980 DOI: 10.1111/Bjh.12978  0.33
2013 Tanios R, Bekdash A, Kassab E, Stone E, Georgiou G, Frankel AE, Abi-Habib RJ. Human recombinant arginase I(Co)-PEG5000 [HuArgI(Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human acute myeloid leukemia cells. Leukemia Research. 37: 1565-71. PMID 24018014 DOI: 10.1016/J.Leukres.2013.08.007  0.74
2013 Kassab E, Darwish M, Timsah Z, Liu S, Leppla SH, Frankel AE, Abi-Habib RJ. Cytotoxicity of anthrax lethal toxin to human acute myeloid leukemia cells is nonapoptotic and dependent on extracellular signal-regulated kinase 1/2 activity. Translational Oncology. 6: 25-32. PMID 23418614 DOI: 10.1593/Tlo.12313  0.733
2013 Yang X, Kessler E, Su LJ, Thorburn A, Frankel AE, Li Y, La Rosa FG, Shen J, Li CY, Varella-Garcia M, Glodé LM, Flaig TW. Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 148-57. PMID 23172881 DOI: 10.1158/1078-0432.Ccr-12-1258  0.44
2012 Agrawal V, Woo JH, Mauldin JP, Jo C, Stone EM, Georgiou G, Frankel AE. Cytotoxicity of human recombinant arginase I (Co)-PEG5000 in the presence of supplemental L-citrulline is dependent on decreased argininosuccinate synthetase expression in human cells. Anti-Cancer Drugs. 23: 51-64. PMID 21955999 DOI: 10.1097/Cad.0B013E32834Ae42B  0.358
2011 Flaig TW, Su L, Thorburn A, Frankel AE, Li Y, Woo JH, Varella-Garcia M, La Rosa FG, Li C, Yang X. DAB389 EGF for the treatment of superficial urothelial cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 255. PMID 27968507 DOI: 10.1200/Jco.2011.29.7_Suppl.255  0.344
2011 Yang MY, Chaudhary A, Seaman S, Dunty J, Stevens J, Elzarrad MK, Frankel AE, St Croix B. The cell surface structure of tumor endothelial marker 8 (TEM8) is regulated by the actin cytoskeleton. Biochimica Et Biophysica Acta. 1813: 39-49. PMID 21129411 DOI: 10.1016/j.bbamcr.2010.11.013  0.303
2010 Frolova O, Frankel AE, Korchin B, Cortes J, Kantarjian HM, Andreeff M, Konopleva M. IL3R Directed Agents, SL-401 and SL-501, Inhibit the Growth of Leukemia Stem Cells In CML. Blood. 116: 3403-3403. DOI: 10.1182/Blood.V116.21.3403.3403  0.369
2009 Horita H, Thorburn J, Frankel AE, Thorburn A. EGFR-targeted diphtheria toxin stimulates TRAIL killing of glioblastoma cells by depleting anti-apoptotic proteins. Journal of Neuro-Oncology. 95: 175-84. PMID 19449148 DOI: 10.1007/S11060-009-9914-4  0.318
2009 Liu S, Bugge TH, Frankel AE, Leppla SH. Dissecting the urokinase activation pathway using urokinase-activated anthrax toxin Methods in Molecular Biology. 539: 175-190. PMID 19377974 DOI: 10.1007/978-1-60327-003-8_10  0.354
2009 Frankel AE, Kuo SR, Dostal D, Watson L, Duesbery NS, Cheng CP, Cheng HJ, Leppla SH. Pathophysiology of anthrax. Frontiers in Bioscience (Landmark Edition). 14: 4516-24. PMID 19273366 DOI: 10.2741/3544  0.342
2009 Thorburn J, Frankel AE, Thorburn A. Regulation of HMGB1 release by autophagy. Autophagy. 5: 247-9. PMID 19098461 DOI: 10.4161/Auto.5.2.7552  0.421
2009 Frolova O, Wang R, Korchin B, Watt JC, Cortes J, Frankel AE, Kantarjian HM, Andreeff M, Konopleva M. Targeting IL3 Receptor in Chronic Myeloid Leukemia. Blood. 114: 2172-2172. DOI: 10.1182/Blood.V114.22.2172.2172  0.321
2008 Horita H, Frankel AE, Thorburn A. Acute myeloid leukemia-targeted toxin activates both apoptotic and necroptotic death mechanisms. Plos One. 3: e3909. PMID 19079542 DOI: 10.1371/Journal.Pone.0003909  0.327
2008 Hall PD, Beagle KL, Garrett-Mayer E, Frankel AE. Reducing anti-DT IgG concentrations to improve the efficacy of a diphtheria fusion protein. Anti-Cancer Drugs. 19: 1007-11. PMID 18827566 DOI: 10.1097/Cad.0B013E328310894F  0.317
2008 Alfano RW, Leppla SH, Liu S, Bugge TH, Herlyn M, Smalley KS, Bromberg-White JL, Duesbery NS, Frankel AE. Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells. Molecular Cancer Therapeutics. 7: 1218-26. PMID 18483309 DOI: 10.1158/1535-7163.Mct-08-0024  0.415
2008 Rouleau C, Menon K, Boutin P, Guyre C, Yoshida H, Kataoka S, Perricone M, Shankara S, Frankel AE, Duesbery NS, Vande Woude G, Biemann HP, Teicher BA. The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: assessment of receptor contribution. International Journal of Oncology. 32: 739-48. PMID 18360701 DOI: 10.3892/Ijo.32.4.739  0.473
2008 Liu S, Wang H, Currie BM, Molinolo A, Leung HJ, Moayeri M, Basile JR, Alfano RW, Gutkind JS, Frankel AE, Bugge TH, Leppla SH. Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. The Journal of Biological Chemistry. 283: 529-40. PMID 17974567 DOI: 10.1074/Jbc.M707419200  0.385
2007 Depeille P, Young JJ, Boguslawski EA, Berghuis BD, Kort EJ, Resau JH, Frankel AE, Duesbery NS. Anthrax lethal toxin inhibits growth of and vascular endothelial growth factor release from endothelial cells expressing the human herpes virus 8 viral G protein coupled receptor. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5926-34. PMID 17908989 DOI: 10.1158/1078-0432.Ccr-07-0732  0.358
2007 Singh R, Browning JL, Abi-Habib R, Wong K, Williams SA, Merchant R, Denmeade SR, Buckley TJ, Frankel AE. Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity. Anti-Cancer Drugs. 18: 809-16. PMID 17581303 DOI: 10.1097/Cad.0B013E3280Bad82D  0.683
2007 Frankel AE, Weir MA, Hall PD, Holguin M, Cable C, Rizzieri DA, Hogge DE. Induction of remission in patients with acute myeloid leukemia without prolonged myelosuppression using diphtheria toxin-interleukin 3 fusion protein Journal of Clinical Oncology. 25: 7068-7068. DOI: 10.1200/Jco.2007.25.18_Suppl.7068  0.361
2006 Abi-Habib RJ, Singh R, Leppla SH, Greene JJ, Ding Y, Berghuis B, Duesbery NS, Frankel AE. Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 7437-43. PMID 17189417 DOI: 10.1158/1078-0432.Ccr-06-2019  0.732
2006 Abi-Habib RJ, Singh R, Liu S, Bugge TH, Leppla SH, Frankel AE. A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types. Molecular Cancer Therapeutics. 5: 2556-62. PMID 17041100 DOI: 10.1158/1535-7163.Mct-06-0315  0.728
2006 Yalcintepe L, Frankel AE, Hogge DE. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. Blood. 108: 3530-7. PMID 16882709 DOI: 10.1182/Blood-2006-04-013813  0.362
2006 Hall PD, Sinha D, Frankel AE. Fresh frozen plasma and platelet concentrates may increase plasma anti-diphtheria toxin IgG concentrations: Implications for diphtheria fusion protein therapy. Cancer Immunology, Immunotherapy : Cii. 55: 928-32. PMID 16645883 DOI: 10.1007/S00262-006-0124-Z  0.308
2006 Hogge DE, Yalcintepe L, Wong SH, Gerhard B, Frankel AE. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1284-91. PMID 16489085 DOI: 10.1158/1078-0432.Ccr-05-2070  0.327
2006 Frankel AE, Weir MA, Hall PD, Hogge DE, Rizzieri DA. Diptheria toxin-interleukin 3 fusion protein therapy of patients with elderly or relapsed/refractory acute myeloid leukemia (AML) Journal of Clinical Oncology. 24: 6569-6569. DOI: 10.1200/Jco.2006.24.18_Suppl.6569  0.365
2005 Wong L, Suh DY, Frankel AE. Toxin conjugate therapy of cancer. Seminars in Oncology. 32: 591-5. PMID 16338425 DOI: 10.1053/J.Seminoncol.2005.08.002  0.326
2005 Abi-Habib RJ, Urieto JO, Liu S, Leppla SH, Duesbery NS, Frankel AE. BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin. Molecular Cancer Therapeutics. 4: 1303-10. PMID 16170021 DOI: 10.1158/1535-7163.Mct-05-0145  0.765
2005 Testa U, Riccioni R, Biffoni M, Diverio D, Lo-Coco F, Foà R, Peschle C, Frankel AE. Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression. Blood. 106: 2527-9. PMID 15928038 DOI: 10.1182/Blood-2005-02-0540  0.367
2005 Frankel AE. New anti-T cell immunotoxins for the clinic. Leukemia Research. 29: 249-51. PMID 15661259 DOI: 10.1016/J.Leukres.2004.08.011  0.308
2005 Cohen KA, Liu TF, Cline JM, Wagner JD, Hall PD, Frankel AE. Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey. Cancer Immunology, Immunotherapy : Cii. 54: 799-806. PMID 15614527 DOI: 10.1007/S00262-004-0643-4  0.332
2005 Frankel AE, Abi-Habib RJ, Urieto JO, Liu S, Leppla SH, van de Woude GF, Duesbery NS. Anthrax tumor toxin (LeTx) selectively kills B-RAF mutant melanomas Journal of Clinical Oncology. 23: 7533-7533. DOI: 10.1200/Jco.2005.23.16_Suppl.7533  0.726
2005 Lilly M, Kuriakose P, Turturro F, Berdeja J, Kerr R, Surendranathan A, Black J, Frankel A. A phase II study of denileukin diftitox (ONTAK) in patients with fludarabine-refractory B-cell chronic lymphocytic leukemia Journal of Clinical Oncology. 23: 6649-6649. DOI: 10.1200/Jco.2005.23.16_Suppl.6649  0.387
2004 Westcott MM, Abi-Habib RJ, Cohen KA, Willingham MC, Liu S, Bugge TH, Leppla SH, Frankel AE. Diphtheria toxin-murine granulocyte-macrophage colony-stimulating factor-induced hepatotoxicity is mediated by Kupffer cells. Molecular Cancer Therapeutics. 3: 1681-9. PMID 15634662  0.725
2004 Hogge DE, Feuring-Buske M, Gerhard B, Frankel AE. The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia. Leukemia Research. 28: 1221-6. PMID 15380349 DOI: 10.1016/J.Leukres.2004.03.015  0.373
2004 Cohen KA, Liu TF, Cline JM, Wagner JD, Hall PD, Frankel AE. Toxicology and pharmacokinetics of DT388IL3, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human interleukin 3 (IL3), in cynomolgus monkeys. Leukemia & Lymphoma. 45: 1647-56. PMID 15370220 DOI: 10.1080/10428190410001663572  0.327
2004 Abi-Habib RJ, Liu S, Bugge TH, Leppla SH, Frankel AE. A urokinase-activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blasts. Blood. 104: 2143-8. PMID 15161668 DOI: 10.1182/Blood-2004-01-0339  0.765
2004 Jedema I, Barge RM, Frankel AE, Willemze R, Falkenburg JH. Acute myeloid leukemia cells in G0 phase of the cell cycle that are unresponsive to conventional chemotherapy are sensitive to treatment with granulocyte-macrophage colony-stimulating factor/diphtheria toxin fusion proteins. Experimental Hematology. 32: 188-94. PMID 15102480 DOI: 10.1016/J.Exphem.2003.11.005  0.488
2004 Liu TF, Urieto JO, Moore JE, Miller MS, Lowe AC, Thorburn A, Frankel AE. Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity. Experimental Hematology. 32: 277-81. PMID 15003313 DOI: 10.1016/J.Exphem.2003.11.010  0.391
2004 Thorburn A, Thorburn J, Frankel AE. Induction of apoptosis by tumor cell-targeted toxins. Apoptosis. 9: 19-25. PMID 14739595 DOI: 10.1023/B:Appt.0000012118.95548.88  0.403
2004 Frankel AE. Reducing the immune response to immunotoxin. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 13-5. PMID 14734445 DOI: 10.1158/1078-0432.Ccr-1216-3  0.359
2004 Urieto JO, Liu T, Black JH, Cohen KA, Hall PD, Willingham MC, Pennell LK, Hogge DE, Kreitman RJ, Frankel AE. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Expression and Purification. 33: 123-33. PMID 14680969 DOI: 10.1016/J.Pep.2003.09.003  0.388
2004 Frankel AE, Liu TF, Thorburn AM, Tatter SB, Willingham MC. Recombinant toxin DAB389EGF produces regressions of human glioma xenografts in nude mice Journal of Clinical Oncology. 22: 3101-3101. DOI: 10.1200/Jco.2004.22.90140.3101  0.397
2004 Kuriakose P, Turturro F, Berdeja JG, Kerr R, Surendranathan A, Black J, Frankel AE. A Phase II Study of Denileukin Diftitox (ONTAK R ) in Patients with Fludarabine Refractory B-Cell Chronic Lymphocytic Leukemia. Blood. 104: 4824-4824. DOI: 10.1182/Blood.V104.11.4824.4824  0.357
2004 Misra D, Frankel A, Hall P, Liu TF, Black J, Moore JO, de Castro C, Gockerman JP, Gasparetto C, Horwitz M, Davis PH, Chao NJ, Rizzieri DA. The Use of DT388-IL3 Fusion Protein in Patients with Refractory Acute Myeloid Leukemia(AML). Blood. 104: 4513-4513. DOI: 10.1182/Blood.V104.11.4513.4513  0.383
2004 Wong SH, Frankel AE, Hogge DE. Variant Forms of Human Interleukin-3 (IL-3) Linked to Truncated Diphtheria Toxin (DT388), Have Enhanced Cytotoxicity Against Acute Myeloid Leukemia (AML) Progenitors. Blood. 104: 1797-1797. DOI: 10.1182/Blood.V104.11.1797.1797  0.399
2003 Liu TF, Cohen KA, Willingham MC, Tatter SB, Puri RK, Frankel AE. Combination fusion protein therapy of refractory brain tumors: demonstration of efficacy in cell culture. Journal of Neuro-Oncology. 65: 77-85. PMID 14649887 DOI: 10.1023/A:1026286214901  0.4
2003 Liu TF, Willingham MC, Tatter SB, Cohen KA, Lowe AC, Thorburn A, Frankel AE. Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells. Bioconjugate Chemistry. 14: 1107-14. PMID 14624623 DOI: 10.1021/Bc034111+  0.489
2003 Frankel AE, Koo HM, Leppla SH, Duesbery NS, Vande Woude GF. Novel protein targeted therapy of metastatic melanoma. Current Pharmaceutical Design. 9: 2060-6. PMID 14552326 DOI: 10.2174/1381612033454162  0.445
2003 Mishra G, Liu TF, Frankel AE. Recombinant toxin DAB389EGF is cytotoxic to human pancreatic cancer cells. Expert Opinion On Biological Therapy. 3: 1173-80. PMID 14519080 DOI: 10.1517/14712598.3.7.1173  0.347
2003 Frankel AE, Neville DM, Bugge TA, Kreitman RJ, Leppla SH. Immunotoxin therapy of hematologic malignancies. Seminars in Oncology. 30: 545-57. PMID 12939723 DOI: 10.1016/S0093-7754(03)00241-0  0.416
2003 Frankel AE, Fleming DR, Powell BL, Gartenhaus R. DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia. Expert Opinion On Biological Therapy. 3: 179-86. PMID 12718740 DOI: 10.1517/14712598.3.1.179  0.387
2003 Liu TF, Cohen KA, Ramage JG, Willingham MC, Thorburn AM, Frankel AE. A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells. Cancer Research. 63: 1834-7. PMID 12702570  0.334
2003 Thorburn J, Frankel AE, Thorburn A. Apoptosis by leukemia cell-targeted diphtheria toxin occurs via receptor-independent activation of Fas-associated death domain protein. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 861-5. PMID 12576460  0.338
2003 Cohen KA, Liu T, Bissonette R, Puri RK, Frankel AE. DAB389EGF fusion protein therapy of refractory glioblastoma multiforme. Current Pharmaceutical Biotechnology. 4: 39-49. PMID 12570681 DOI: 10.2174/1389201033378039  0.39
2003 Black JH, McCubrey JA, Willingham MC, Ramage J, Hogge DE, Frankel AE. Diphtheria-toxin-interleukin-3 fusion protein (DT388IL3) prolongs disease-free survival of leukemic immunocompromised mice Leukemia. 17: 155-159. PMID 12529673 DOI: 10.1038/Sj.Leu.2402744  0.356
2003 Ramage JG, Vallera DA, Black JH, Aplan PD, Kees UR, Frankel AE. The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells. Leukemia Research. 27: 79-84. PMID 12479856 DOI: 10.1016/S0145-2126(02)00077-2  0.382
2003 Riedlinger G, Kridel S, Al-Housseini AM, Brow JM, Bugge TH, Leppla SH, Duesbery N, Woude GV, Frankel A. Metastatic melanoma and matrix metalloproteinases Drugs of the Future. 28: 897-904. DOI: 10.1358/Dof.2003.028.09.857377  0.355
2002 Roboz GJ, Knovich MA, Bayer RL, Schuster MW, Seiter K, Powell BL, Woodruff RD, Silver RT, Frankel AE, Feldman EJ. Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia. Leukemia & Lymphoma. 43: 1951-5. PMID 12481890 DOI: 10.1080/1042819021000016078  0.301
2002 Frankel AE. Receptor upregulation enhances cell surface receptor targeted therapies. Leukemia Research. 26: 1069-71. PMID 12443877 DOI: 10.1016/S0145-2126(02)00066-8  0.427
2002 Frankel AE, Beran M, Hogge DE, Powell BL, Thorburn A, Chen YQ, Vallera DA. Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein. Experimental Hematology. 30: 1316-23. PMID 12423685 DOI: 10.1016/S0301-472X(02)00925-6  0.42
2002 Frankel AE, Powell BL, Duesbery NS, Vande Woude GF, Leppla SH. Anthrax fusion protein therapy of cancer. Current Protein & Peptide Science. 3: 399-407. PMID 12370003 DOI: 10.2174/1389203023380567  0.456
2002 Hall PD, Razzouk BI, Willoughby TE, McLean TW, Frankel AE. The majority of children and adolescents with acute myeloid leukemia have detectable anti-DT388-GMCSF IgG concentrations, but at concentrations that should not preclude in vivo activity. Journal of Pediatric Hematology/Oncology. 24: 521-6. PMID 12368687 DOI: 10.1097/00043426-200210000-00005  0.302
2002 Frankel AE, Rossi P, Kuzel TM, Foss F. Diphtheria fusion protein therapy of chemoresistant malignancies. Current Cancer Drug Targets. 2: 19-36. PMID 12188918 DOI: 10.2174/1568009023333944  0.442
2002 Frankel AE, Bugge TH, Liu S, Vallera DA, Leppla SH. Peptide toxins directed at the matrix dissolution systems of cancer cells. Protein and Peptide Letters. 9: 1-14. PMID 12141918 DOI: 10.2174/0929866023409048  0.366
2002 Thomas PB, Delatte SJ, Sutphin A, Frankel AE, Tagge EP. Effective targeted cytotoxicity of neuroblastoma cells. Journal of Pediatric Surgery. 37: 539-44. PMID 11877684 DOI: 10.1053/Jpsu.2002.30856  0.416
2001 Alexander RL, Ramage J, Kucera GL, Caligiuri MA, Frankel AE. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein Leukemia Research. 25: 875-881. PMID 11532521 DOI: 10.1016/S0145-2126(01)00034-0  0.352
2001 Frankel AE, Baer MR, Hogge DE, Stuart RK. Immunotherapy of acute myeloid leukemia Current Pharmaceutical Biotechnology. 2: 209-215. PMID 11530875 DOI: 10.2174/1389201013378699  0.396
2001 Hall PD, Virella G, Willoughby T, Atchley DH, Kreitman RJ, Frankel AE. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia. Clinical Immunology (Orlando, Fla.). 100: 191-7. PMID 11465948 DOI: 10.1006/Clim.2001.5066  0.359
2001 Frankel AE, Schuster MW, Jurcic JG. Novel therapeutics for chemotherapy-resistant acute myeloid leukaemia. Biodrugs. 15: 55-71. PMID 11437675 DOI: 10.2165/00063030-200115010-00005  0.4
2001 Lilly MB, Zemskova M, Frankel AE, Salo J, Kraft AS. Distinct domains of the human granulocyte-macrophage colony-stimulating factor receptor α subunit mediate activation of Jak/Stat signaling and differentiation Blood. 97: 1662-1670. PMID 11238105 DOI: 10.1182/Blood.V97.6.1662  0.33
2001 Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 376-88. PMID 11208829 DOI: 10.1200/Jco.2001.19.2.376  0.312
2000 Frankel AE, Sievers EL, Scheinberg DA. Cell surface receptor-targeted therapy of acute myeloid leukemia: A review Cancer Biotherapy and Radiopharmaceuticals. 15: 459-476. PMID 11155818 DOI: 10.1089/Cbr.2000.15.459  0.463
2000 Feuring-Buske M, Frankel AE, Gerhard B, Hogge D. Variable cytotoxicity of diphtheria toxin 388–granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells Experimental Hematology. 28: 1390-1400. PMID 11146161 DOI: 10.1016/S0301-472X(00)00542-7  0.432
2000 Frankel AE, Ramage J, Kiser M, Alexander R, Kucera G, Miller MS. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor Protein Engineering. 13: 575-581. PMID 10964987 DOI: 10.1093/Protein/13.8.575  0.41
2000 Alexander RL, Kucera GL, Klein B, Frankel AE. In vitro interleukin-3 binding to leukemia cells predicts cytotoxicity of a diphtheria toxin/IL-3 fusion protein. Bioconjugate Chemistry. 11: 564-568. PMID 10898579 DOI: 10.1021/Bc000009Q  0.434
2000 Frankel AE, McCubrey JA, Miller MS, Delatte S, Ramage J, Kiser M, Kucera GL, Alexander RL, Beran M, Tagge EP, Kreitman RJ, Hogge DE. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. Leukemia. 14: 576-85. PMID 10764142 DOI: 10.1038/Sj.Leu.2401743  0.464
2000 Feuring-Buske M, Frankel A, Gerhard B, Hogge D. Selective cytotoxicity of diphtheria toxin-interleukin 3 fusion protein for acute myeloid leukemia (Aml) Stem cells Experimental Hematology. 28: 81. DOI: 10.1016/S0301-472X(00)00340-4  0.421
1999 Frankel AE, Ramage J, Latimer A, Feely T, Delatte S, Hall P, Tagge E, Kreitman R, Willingham M. High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials Protein Expression and Purification. 16: 190-201. PMID 10336877 DOI: 10.1006/Prep.1999.1071  0.365
1999 Hall PD, Willingham MC, Kreitman RJ, Frankel AE. DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia Leukemia. 13: 629-633. PMID 10214872 DOI: 10.1038/Sj.Leu.2401357  0.333
1998 Frankel AE, Hall PD, McLain C, Safa AR, Tagge EP, Kreitman RJ. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF. Bioconjugate Chemistry. 9: 490-6. PMID 9667951 DOI: 10.1021/Bc980015A  0.438
1998 Hall PD, Kreitman RJ, Willingham MC, Frankel AE. Toxicology and pharmacokinetics of DT388-GM-CSF, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor (GM-CSF)in C57BL/6 mice Toxicology and Applied Pharmacology. 150: 91-97. PMID 9630457 DOI: 10.1006/Taap.1998.8389  0.369
1998 Duvic M, Cather J, Maize J, Frankel AE. Dab389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma American Journal of Hematology. 58: 87-90. PMID 9590158 DOI: 10.1002/(Sici)1096-8652(199805)58:1<87::Aid-Ajh18>3.0.Co;2-2  0.346
1998 Byeon MK, Frankel A, Papas TS, Henderson KW, Schweinfest CW. Human DRA functions as a sulfate transporter in Sf9 insect cells. Protein Expression and Purification. 12: 67-74. PMID 9473459 DOI: 10.1006/Prep.1997.0809  0.336
1998 Hogge DE, Willman CL, Kreitman RJ, Berger M, Hall PD, Kopecky KJ, McLain C, Tagge EP, Eaves CJ, Frankel AE. Malignant Progenitors From Patients With Acute Myelogenous Leukemia Are Sensitive to a Diphtheria Toxin-Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein Blood. 92: 589-595. DOI: 10.1182/Blood.V92.2.589.414K20_589_595  0.458
1998 Frankel AE, Lilly M, Kreitman R, Hogge D, Beran M, Freedman MH, Emanuel PD, McLain C, Hall P, Tagge E, Berger M, Eaves C. Diphtheria Toxin Fused to Granulocyte-Macrophage Colony-Stimulating Factor Is Toxic to Blasts From Patients With Juvenile Myelomonocytic Leukemia and Chronic Myelomonocytic Leukemia Blood. 92: 4279-4286. DOI: 10.1182/Blood.V92.11.4279.423K26_4279_4286  0.451
1997 Tagge E, Harris B, Burbage C, Hall P, Vesely J, Willingham M, Frankel A. Synthesis of green fluorescent protein-ricin and monitoring of its intracellular trafficking Bioconjugate Chemistry. 8: 743-750. PMID 9327140 DOI: 10.1021/Bc9700749  0.395
1997 Frankel AE, Laver JH, Willingham MC, Burns LJ, Kersey JH, Vallera DA. Therapy of Patients with T-cell Lymphomas and Leukemias Using an Anti-CD7 Monoclonal Antibody-Rich a Chain Immunotoxin Leukemia & Lymphoma. 26: 287-298. PMID 9322891 DOI: 10.3109/10428199709051778  0.387
1997 Burbage C, Tagge EP, Harris B, Hall P, Fu T, Willingham MC, Frankel AE. Ricin fusion toxin targeted to the human granulocyte-macrophage colony stimulating factor receptor is selectively toxic to acute myeloid leukemia cells. Leukemia Research. 21: 681-90. PMID 9301690 DOI: 10.1016/S0145-2126(97)00043-X  0.486
1997 Frankel AE, Fu T, Burbage C, Tagge E, Harris B, Vesely J, Willingham MC. Lectin-deficient ricin toxin indicates cells bearing the D-mannose receptor Carbohydrate Research. 300: 251-258. PMID 9202409 DOI: 10.1016/S0008-6215(97)00048-7  0.427
1997 Frankel AE, Fu T, Burbage C, Chandler J, Willingham MC, Tagge EP. IL2 fused to lectin-deficient ricin is toxic to human leukemia cells expressing the IL2 receptor. Leukemia. 11: 22-30. PMID 9001414 DOI: 10.1038/Sj.Leu.2400517  0.382
1997 Frankel AE, Hall PD, Burbage C, Vesely J, Willingham M, Bhalla K, Kreitman RJ. Modulation of the Apoptotic Response of Human Myeloid Leukemia Cells to a Diphtheria Toxin Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein Blood. 90: 3654-3661. DOI: 10.1182/Blood.V90.9.3654  0.462
1996 Fu T, Burbage C, Tagge EP, Brothers T, Willingham MC, Frankel AE. Ricin toxin contains three lectin sites which contribute to its in vivo toxicity. International Journal of Immunopharmacology. 18: 685-92. PMID 9172011 DOI: 10.1016/S0192-0561(97)85550-6  0.315
1996 Fu T, Burbage C, Tagge E, Chandler J, Willingham M, Frankel A. Double-lectin site ricin B chain mutants expressed in insect cells have residual galactose binding: Evidence for more than two lectin sites on the ricin toxin B chain Bioconjugate Chemistry. 7: 651-658. PMID 8950484 DOI: 10.1021/Bc960056B  0.357
1996 Frankel AE, Burbage C, Fu T, Tagge E, Chandler J, Willingham MC. Ricin toxin contains at least three galactose-binding sites located in B chain subdomains 1α, 1β, and 2γ Biochemistry. 35: 14749-14756. PMID 8942636 DOI: 10.1021/Bi960798S  0.301
1996 Frankel AE, Burbage C, Fu T, Tagge E, Chandler J, Willingham M. Characterization of a ricin fusion toxin targeted to the interleukin-2 receptor Protein Engineering. 9: 913-919. PMID 8931131 DOI: 10.1093/Protein/9.10.913  0.397
1996 Vallera DA, Burns LJ, Frankel AE, Sicheneder AR, Gunther R, Gajl-Peczalska K, Pennell CA, Kersey JH. Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies. Journal of Immunological Methods. 197: 69-83. PMID 8890895 DOI: 10.1016/0022-1759(96)00127-5  0.418
1996 Tagge EP, Chandler J, Harris B, Czako M, Marton L, Willingham MC, Burbage C, Afrin L, Frankel AE. Preproricin expressed in Nicotiana tabacum cells in vitro is fully processed and biologically active. Protein Expression and Purification. 8: 109-18. PMID 8812841 DOI: 10.1006/Prep.1996.0080  0.417
1996 Frankel A, Tagge E, Chandler J, Burbage C, Hancock G, Vesely J, Willingham M. Characterization of single site ricin toxin B chain mutants. Bioconjugate Chemistry. 7: 30-7. PMID 8741988 DOI: 10.1021/Bc950067P  0.333
1996 Frankel A, Tagge E, Chandler J, Burbage C, Willingham M. Double-site ricin B chain mutants retain galactose binding Protein Engineering. 9: 371-379. PMID 8738213 DOI: 10.1093/Protein/9.4.371  0.34
1996 Tagge E, Chandler J, Tang BL, Hong W, Willingham MC, Frankel A. Cytotoxicity of KDEL-terminated ricin toxins correlates with distribution of the KDEL receptor in the Golgi Journal of Histochemistry and Cytochemistry. 44: 159-165. PMID 8609372 DOI: 10.1177/44.2.8609372  0.422
1995 Frankel A, Tagge E, Chandler J, Burbage C, Hancock G, Vesely J, Willingham M. IL2-ricin fusion toxin is selectively cytotoxic in vitro to IL2 receptor-bearing tumor cells. Bioconjugate Chemistry. 6: 666-72. PMID 8608178 DOI: 10.1021/Bc00036A002  0.394
1995 Frankel AE, Tagge EP, Willingham MC. Clinical trials of targeted toxins. Seminars in Cancer Biology. 6: 307-17. PMID 8562908 DOI: 10.1006/Scbi.1995.0039  0.325
1995 Brothers TE, Robison JG, Elliott BM, Boggs JM, Frankel AE, Willingham MC. Upregulation of b-FGF receptor expression after carotid bypass. The Journal of Surgical Research. 58: 28-32. PMID 7830402 DOI: 10.1006/Jsre.1995.1005  0.331
1994 Frankel A, Roberts H, Gulick H, Afrin L, Vesely J, Willingham M. Expression of ricin B chain in Spodoptera frugiperda. Biochemical Journal. 303: 787-794. PMID 7980448 DOI: 10.1042/Bj3030787  0.326
1994 Afrin LB, Gulick H, Vesely J, Willingham M, Frankel AE. Expression of Oligohistidine-Tagged Ricin B Chain in Spodoptera frugiperda Bioconjugate Chemistry. 5: 539-546. PMID 7533004 DOI: 10.1021/Bc00030A009  0.346
1992 Pai LH, Bookman MA, Ozols RF, Young RC, Smith JW, Longo DL, Gould B, Frankel A, McClay EF, Howell S. Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 9: 2095-103. PMID 1960550 DOI: 10.1200/Jco.1991.9.12.2095  0.311
1991 LeMaistre C, Rosen S, Frankel A, Kornfeld S, Saria E, Meneghetti C, Drajesk J, Fishwild D, Scannon P, Byers V. Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T- cell lymphoma Blood. 78: 1173-1182. DOI: 10.1182/Blood.V78.5.1173.Bloodjournal7851173  0.395
1989 Gould BJ, Borowitz MJ, Groves ES, Carter PW, Anthony D, Weiner LM, Frankel AE. Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies. Journal of the National Cancer Institute. 81: 775-81. PMID 2785605 DOI: 10.1093/Jnci/81.10.775  0.325
1989 Hertler AA, Schlossman DM, Borowitz MJ, Poplack DG, Frankel AE. An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys. Cancer Immunology, Immunotherapy. 28: 59-66. PMID 2783301 DOI: 10.1007/Bf00205802  0.391
1989 Hertler AA, Frankel AE. Immunotoxins: a clinical review of their use in the treatment of malignancies. Journal of Clinical Oncology. 7: 1932-1942. PMID 2685183 DOI: 10.1200/Jco.1989.7.12.1932  0.359
1989 Hertler AA, Schlossman DM, Borowitz MJ, Blythman HE, Casellas P, Frankel AE. An anti-CD5 immunotoxin for chronic lymphocytic leukemia: enhancement of cytotoxicity with human serum albumin-monensin. International Journal of Cancer. 43: 215-219. PMID 2465276 DOI: 10.1002/Ijc.2910430207  0.382
1988 Laurent G, Frankel AE, Hertler AA, Schlossman DM, Casellas P, Jansen FK. Treatment of leukemia patients with T101 ricin A chain immunotoxins. Cancer Treatment and Research. 37: 483-491. PMID 2484640 DOI: 10.1007/978-1-4613-1083-9_27  0.4
1987 Hertler AA, Spitler LE, Frankel AE. Humoral immune response to a ricin A chain immunotoxin in patients with metastatic melanoma Cancer Drug Delivery. 4: 245-253. PMID 3502618 DOI: 10.1089/Cdd.1987.4.245  0.316
1985 Pirker R, FitzGerald DJP, Hamilton TC, Ozols RF, Laird W, Frankel AE, Willingham MC, Pastan I. Characterization of immunotoxins active against ovarian cancer cell lines Journal of Clinical Investigation. 76: 1261-1267. PMID 3930572 DOI: 10.1172/Jci112082  0.423
Show low-probability matches.